8-K: Silo Pharma Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance

Silo Pharma, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance.

Summary

• Silo Pharma, Inc. received a notification from The Nasdaq Stock Market LLC on June 27, 2025, stating non-compliance with Nasdaq Listing Rule 5550(a)(2).
• The rule requires listed securities to maintain a minimum bid price of $1.00 per share.
• The deficiency was identified because the company's common stock closing bid price was below $1.00 for 30 consecutive business days, from May 14, 2025, to June 26, 2025.
• The notification does not immediately affect the listing or trading of Silo Pharma's common stock, which will continue to trade on The Nasdaq Capital Market under the symbol SILO.
• Silo Pharma has 180 calendar days, until December 24, 2025, to regain compliance.
• To regain compliance, the common stock's closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days.
• An additional 180-day compliance period may be granted if the company meets other Nasdaq Capital Market listing requirements and notifies Nasdaq of its intent to cure, potentially through a reverse stock split.
• Failure to regain compliance could lead to delisting, with an opportunity for the company to appeal to a Hearings Panel.
• The company intends to monitor its stock price and consider options, including a reverse stock split, to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (Nasdaq non-compliance) with potential severe consequences (delisting), despite the company having a grace period and considering options. The immediate impact is negative, reflecting a struggle to maintain market valuation.

Positives

• No immediate effect on the listing or trading of the common stock on The Nasdaq Capital Market.
• The company has a defined 180-day period to regain compliance, with a potential for an additional 180 days.
• Management is actively monitoring the situation and considering options, including a reverse stock split, to address the non-compliance.

Negatives

• Silo Pharma is not in compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company's common stock closing bid price has been below $1.00 for 30 consecutive business days (May 14, 2025 to June 26, 2025).
• Failure to regain compliance could result in the delisting of the company's common stock from The Nasdaq Capital Market.

Risks

• Potential delisting of Silo Pharma's common stock from The Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement.
• Risk of further stock price decline if the company does not achieve the $1.00 bid price threshold.
• Risk of a reverse stock split, which can sometimes be perceived negatively by investors and may not guarantee long-term price stability.

Future Outlook

The company has 180 calendar days, until December 24, 2025, to regain compliance with Nasdaq's minimum bid price requirement. If compliance is not met within this period, an additional 180-day period may be granted under certain conditions. The company intends to monitor its common stock's closing bid price and may consider implementing available options, including a reverse stock split, to cure the deficiency.

Management Comments

• The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

Industry Context

This situation is common for smaller capitalization companies or those in emerging sectors that may experience volatility or struggle to maintain investor interest and stock price above exchange minimums. Such notices are a standard regulatory procedure for exchanges to ensure the quality and stability of listed securities.

Comparison to Industry Standards

• Nasdaq's minimum bid price requirement of $1.00 is a standard listing criterion for many major stock exchanges globally, including other segments of Nasdaq and the NYSE, designed to ensure a certain level of market capitalization and liquidity for listed companies.
• Companies like Sorrento Therapeutics (SRNEQ) and Mullen Automotive (MULN) have faced similar Nasdaq delisting notices due to bid price deficiencies, often resorting to reverse stock splits to regain compliance, though the long-term effectiveness of such measures varies.
• The 180-day compliance period, with a potential for an extension, is a standard grace period provided by Nasdaq, offering companies a window to rectify the issue before delisting procedures are initiated.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced liquidity, lower stock price, and potential transfer to over-the-counter markets. A reverse stock split, if implemented, could reduce the number of shares held, though not necessarily the total value immediately.
• Employees: While not directly impacted by this specific notice, sustained financial distress or delisting could indirectly affect employee morale or future prospects.
• Customers/Suppliers: Unlikely to be directly impacted by a listing compliance issue, unless it signals broader financial instability that affects operations.
• Creditors: May view the company with increased scrutiny due to the delisting risk, potentially impacting future credit terms or access to capital.

Next Steps

• Monitor the closing bid price of the common stock.
• Regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by December 24, 2025.
• Consider implementing available options, including a reverse stock split, if necessary, to regain compliance.
• If compliance is not met, potentially apply for a second 180-day compliance period by meeting other Nasdaq listing standards and notifying Nasdaq of intent to cure.
• Prepare for a potential appeal to a Hearings Panel if Nasdaq determines to delist the common stock.

Key Dates

Recommendation

Keywords

Silo Pharma, Nasdaq, delisting, minimum bid price, non-compliance, stock market, common stock, reverse stock split, Nasdaq Capital Market, SILO, 8-K filing